CAMBRIDGE, Mass., Feb. 9 /PRNewswire/ -- Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
“Ligon’s Small Molecule Microarray technology allows us to rapidly screen any protein target irrespective of its biological function, against Ligon’s and our compound collection,” said Dr. Gary Glick, Lycera’s founder and Chief Scientific Officer.
Ligon Discovery
